Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
Clinical trial NCT03423992 · UNKNOWN
Trial details
- NCT number
- NCT03423992
- Sponsor
- Xuanwu Hospital, Beijing
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-02
- Primary completion
- 2023-01-30
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.